Twinbeech Capital LP Incyte Corp Transaction History

Twinbeech Capital LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$57.77 - $65.93 $20.7 Million - $23.6 Million	358,295 New	358,295 $20.7 Million
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $3.75 Million - $4.69 Million	55,784 Added 516.47%	66,585 $5.35 Million
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $714,810 - $894,970	10,801 New	10,801 $720,000
Q4 2021 Feb 14, 2022	SELL	$63.34 - $74.11 $3.85 Million - $4.5 Million	-60,788 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$68.67 - $84.02 $4.17 Million - $5.11 Million	60,788 New	60,788 $4.18 Million
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $1 Million - $1.36 Million	-15,833 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$73.04 - $95.72 $1.16 Million - $1.52 Million	15,833 New	15,833 $1.38 Million

649

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.